{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:43:36Z","timestamp":1753868616744,"version":"3.41.2"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational All"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with severe asthma experience decreased quality of life due to fixed airway obstruction, hospitalisations and potential fatalities. However, to date, the requalification of severe asthma patients eligible for biological therapy in daily clinical practice remains unstudied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of the study was to prepare a universal decision\u2010making algorithm for requalifying patients for biological therapy based on available clinical data obtained from a leading reference centre in Poland.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All severe asthma patients treated with biologics since 2013 at the Internal Medicine, Asthma and Allergy Department (Medical University of Lodz, Poland), were analysed. The analysis included demographic (age, sex), pre\u2010treatment (reported at qualification: oral glucocorticosteroids use, total IgE serum level, peripheral blood eosinophilia, co\u2010morbidities: atopic dermatitis, chronic allergic rhinitis or sinusitis) and treatment\u2010related data (treatment time, current treatment status, reason for early termination of therapy, year of discontinuation, rediagnostics, requalification).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Rediagnostics were performed in only 4.76% of all requalifications. The following additional data were used to requalify patients: blood eosinophilia (<jats:italic>n<\/jats:italic>\u00a0=\u00a063; 100.00% of requalifications), atopic comorbidities (<jats:italic>n<\/jats:italic>\u00a0=\u00a030; 47.62%) and total IgE serum level (<jats:italic>n<\/jats:italic>\u00a0=\u00a08; 12.70%). Kaplan\u2013Meier curve analysis of all source data revealed the longevity of maintenance as follows: the highest for mepolizumab, then omalizumab, benralizumab, dupilumab and tezepelumab (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.016). Based on the results, requalification model \u2018ReQuaBi\u2019, was constructed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The most important criteria for selecting a biological agent in requalification are peripheral blood eosinophilia, followed by comorbidities and IgE levels. In most cases, extensive additional re\u2010diagnosis may not be necessary.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clt2.70059","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:45:14Z","timestamp":1746801914000},"source":"Crossref","is-referenced-by-count":0,"title":["Requalification of patients with severe asthma for biological therapy\u2014Practical \u2018ReQuaBi\u2019 rate decision scheme based on the analytical model"],"prefix":"10.1002","volume":"15","author":[{"given":"Alicja","family":"Majos","sequence":"first","affiliation":[{"name":"Department of General and Transplant Surgery Medical University of Lodz  \u0141\u00f3d\u017a Poland"},{"name":"Department of Internal Medicine, Asthma and Allergy Medical University of Lodz  \u0141\u00f3d\u017a Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Ben","family":"Drissi","sequence":"additional","affiliation":[{"name":"Polish Society of Allergology Coalition for Asthma Treatment  \u0141\u00f3d\u017a Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Kupczyk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy Medical University of Lodz  \u0141\u00f3d\u017a Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3718-4793","authenticated-orcid":false,"given":"Micha\u0142","family":"Panek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy Medical University of Lodz  \u0141\u00f3d\u017a Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Global strategy for asthma management and prevention Assessed December 1 2024.https:\/\/ginasthma.org\/2024\u2010report\/"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2032506"},{"key":"e_1_2_10_4_1","unstructured":"2024 Severe Asthma Guide.Diagnosis and management of difficult\u2010to\u2010treat and severe asthma https:\/\/ginasthma.org\/severe\u2010asthma\/"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.042"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00779\u20102015"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.03.008"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0628"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14514"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00117\u20102020"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.10.048"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00761"},{"volume-title":"The Global Asthma Report 2018","year":"2018","author":"Network GA","key":"e_1_2_10_13_1"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2022.2090342"}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:42:36Z","timestamp":1748356956000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.70059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/clt2.70059"],"URL":"https:\/\/doi.org\/10.1002\/clt2.70059","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"type":"print","value":"2045-7022"},{"type":"electronic","value":"2045-7022"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"e70059"}}